Keros Therapeutics (KROS) Operating Income (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Operating Income came in at -$29.3 million in Q4 2025, up 45.04% YoY from -$20.2 million in Q4 2024, and down 90.26% on a QoQ basis from -$15.4 million in Q3 2025.
Keros Therapeutics (KROS) Operating Income (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Operating Income data on file, last reported at -$29.3 million in Q4 2025.
- Quarterly Operating Income rose 45.04% year-over-year to -$29.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.6 million (up 132.05% YoY) and the FY2025 annual result came in at $67.6 million, up 132.05% from the prior year.
- Operating Income declined to -$29.3 million in Q4 2025, from -$15.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $152.0 million in Q1 2025 to a low of -$58.7 million in Q3 2024.
- A 5-year average of -$24.2 million and a median of -$31.3 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income sank 556.8% — and 2025, when it surged 413.59%.
- Tracing KROS's Operating Income over 5 years: stood at -$4.9 million in 2021, then slumped by 556.8% to -$32.0 million in 2022, then slumped by 45.35% to -$46.5 million in 2023, then retreated by 14.64% to -$53.3 million in 2024, then soared by 45.04% to -$29.3 million in 2025.
- The last three Operating Income figures came in at -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -30.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.94 Mn |
| Dec 31, 2025 | -29.27 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -39.82 Mn |
| Mar 31, 2025 | 152.04 Mn |
| Dec 31, 2024 | -53.25 Mn |
| Sep 30, 2024 | -58.66 Mn |
| Jun 30, 2024 | -50.44 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -43.28 Mn |
| Jun 30, 2023 | -41.34 Mn |
| Mar 31, 2023 | -38.87 Mn |
| Dec 31, 2022 | -31.96 Mn |
| Sep 30, 2022 | -27.98 Mn |
| Jun 30, 2022 | -30.73 Mn |
| Mar 31, 2022 | -24.13 Mn |
| Dec 31, 2021 | -4.87 Mn |
| Sep 30, 2021 | -20.20 Mn |
| Jun 30, 2021 | -15.54 Mn |